English

ATYR PHARMA, INC.

EDGAR

ATYR Current report (8-K) · filed 2026-10-27

Annual consolidated revenue for 2025: about USD 190K, using the latest reported figures. The previous period, 2024, was about USD 235K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2025 Q4 · USD

Exact inputs and evidence

Revenue: 190000 USD Source
Revenue: 190000 USD Source

Operating cash flow

-12.2 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -61986000 USD Source
Operating Cash Flow: -49790000 USD Source

Free cash flow

-12.2 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -61986000 USD Source
Operating Cash Flow: -49790000 USD Source
Capital Expenditure: 77000 USD Source
Capital Expenditure: 46000 USD Source

Cash and cash equivalents: 16.2 million USD 2026-06-30 Source
Exact value

16160000 USD
Long-term debt including current maturities: 15.3 million USD 2018-12-31 Source
Exact value

15333000 USD
Shares outstanding: 98.1 million shares 2026-06-30 Source
Exact value

98087425 shares

Reported share-count change

5.62% · 5.22 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

92871182 shares · 2025-06-30· Source
98087425 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

190 thousand USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Revenue: 0 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 0 USD · 2025-04-01 – 2025-06-30 Source
Revenue: 190000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 190000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 190000 USD · 2025-01-01 – 2025-09-30 Source

Net income

-60.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -25700000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -74118000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -60200000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -10800000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -10300000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-54.5 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -49790000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -29314000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -61986000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -49790000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -12517000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -21868000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -12517000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

279 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 46000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 9000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 77000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 46000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 138000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 211000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 138000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-54.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -49790000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -29314000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -61986000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -49790000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -12517000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -21868000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -12517000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 46000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 9000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 77000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 46000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 138000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 211000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 138000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-27.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
liabilities: No compatible figures in this window
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-19.1%

Prior period

USD 235,000

2024-01-01 – 2024-12-31
Current period

USD 190,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

190000 − 235000 = -45000 USD

235000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
190000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ATYR PHARMA, INC. · 2025-12-31 ATYR PHARMA, INC. (edgar:1339970) Year-over-year change in Revenue: -45000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 190000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1828655 Filing: 000133997026000008 Input fundies:Revenue: 235000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1830329 Filing: 000133997026000008
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 10.1 million

Prior period

−USD 64.02 million

2024-01-01 – 2024-12-31
Current period

−USD 74.12 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-74118000 − -64023000 = -10095000 USD

-64023000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-74118000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ATYR PHARMA, INC. · 2025-12-31 ATYR PHARMA, INC. (edgar:1339970) Year-over-year change in Net income: -10095000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -74118000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1996626 Filing: 000133997026000008 Input fundies:NetIncome: -64023000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1998467 Filing: 000133997026000008
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 7.13 million

Prior period

−USD 69.12 million

2024-01-01 – 2024-12-31
Current period

−USD 61.99 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-61986000 − -69119000 = 7133000 USD

-69119000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-61986000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ATYR PHARMA, INC. · 2025-12-31 ATYR PHARMA, INC. (edgar:1339970) Year-over-year change in Operating cash flow: 7133000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -61986000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1661152 Filing: 000133997026000008 Input fundies:OperatingCashFlow: -69119000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1662903 Filing: 000133997026000008
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+18.5%

Prior period

USD 65,000

2024-01-01 – 2024-12-31
Current period

USD 77,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

77000 − 65000 = 12000 USD

65000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
77000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ATYR PHARMA, INC. · 2025-12-31 ATYR PHARMA, INC. (edgar:1339970) Year-over-year change in Capital expenditure: 12000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 77000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1670421 Filing: 000133997026000008 Input fundies:CapitalExpenditure: 65000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1672159 Filing: 000133997026000008
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 190,000 100% of revenue
Operating costs Derived USD 77.82 million 40,956% of revenue
Operating income −USD 77.63 million −40,856% of revenue
Tax, interest and other Derived −USD 3.51 million −1,847% of revenue
Net income −USD 74.12 million −39,009% of revenue

Cash

Operating cash flow −USD 61.99 million −32,624% of revenue
Capital expenditure USD 77,000 41% of revenue
Free cash flow Derived −USD 62.06 million −32,665% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 5,545% of revenue.
2020 Operating loss: operating costs were 252% of revenue.
2021 Not shown: operating income or net income is not reported.
2022 Operating loss: operating costs were 547% of revenue.
2023 Operating loss: operating costs were 15,658% of revenue.
2024 Operating loss: operating costs were 29,000% of revenue.
2025 Operating loss: operating costs were 40,956% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	422000	23400000 Derived	-22978000	-6754000 Derived	-16224000	-20092000 Derived	Source 2019-01-01 – 2019-12-31: 422000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -22978000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -16224000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -20013000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 79000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	10455000	26366000 Derived	-15911000	313000 Derived	-16224000	-15503000 Derived	Source 2020-01-01 – 2020-12-31: 10455000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -15911000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -16224000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -15301000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 202000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	0	34015000 Derived	-34015000	-247000 Derived	-33768000	-33267000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -34015000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -33768000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -33075000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 192000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	10386000	56790000 Derived	-46404000	-1066000 Derived	-45338000	-43527000 Derived	Source 2022-01-01 – 2022-12-31: 10386000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -46404000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -45338000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -41886000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1641000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	353000	55272000 Derived	-54919000	-4530000 Derived	-50389000	-37436000 Derived	Source 2023-01-01 – 2023-12-31: 353000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -54919000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -50389000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -33221000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 4215000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	235000	68149000 Derived	-67914000	-3891000 Derived	-64023000	-69184000 Derived	Source 2024-01-01 – 2024-12-31: 235000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -67914000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -64023000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -69119000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 65000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	190000	77817000 Derived	-77627000	-3509000 Derived	-74118000	-62063000 Derived	Source 2025-01-01 – 2025-12-31: 190000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -77627000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -74118000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -61986000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 77000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 190K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	422000	Revenue: 422000 Open source
20202020-12-31	Revenue	10455000	Revenue: 10455000 Open source
20212021-12-31	Revenue	0	Revenue: 0 Open source
20222022-12-31	Revenue	10386000	Revenue: 10386000 Open source
20232023-12-31	Revenue	353000	Revenue: 353000 Open source
20242024-12-31	Revenue	235000	Revenue: 235000 Open source
20252025-12-31	Revenue	190000	Revenue: 190000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-19.1% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 422000 Open source
20202020-12-31	Year over year	2,377.5%	Revenue: 10455000 Open source Revenue: 422000 Open source
20212021-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 10455000 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 10386000 Open source Revenue: 0 Open source
20232023-12-31	Year over year	-96.6%	Revenue: 353000 Open source Revenue: 10386000 Open source
20242024-12-31	Year over year	-33.4%	Revenue: 235000 Open source Revenue: 353000 Open source
20252025-12-31	Year over year	-19.1%	Revenue: 190000 Open source Revenue: 235000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -40,856.3% 2025

Net margin -39,009.5% 2025

Free cash flow margin -32,664.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-5,445%	Operating Income: -22978000 Open source Revenue: 422000 Open source
20202020-12-31	Operating margin	-152.2%	Operating Income: -15911000 Open source Revenue: 10455000 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -34015000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	-446.8%	Operating Income: -46404000 Open source Revenue: 10386000 Open source
20232023-12-31	Operating margin	-15,557.8%	Operating Income: -54919000 Open source Revenue: 353000 Open source
20242024-12-31	Operating margin	-28,899.6%	Operating Income: -67914000 Open source Revenue: 235000 Open source
20252025-12-31	Operating margin	-40,856.3%	Operating Income: -77627000 Open source Revenue: 190000 Open source
20192019-12-31	Net margin	-3,844.5%	Net Income: -16224000 Open source Revenue: 422000 Open source
20202020-12-31	Net margin	-155.2%	Net Income: -16224000 Open source Revenue: 10455000 Open source
20212021-12-31	Net margin	Not reported	Net Income: -33768000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	-436.5%	Net Income: -45338000 Open source Revenue: 10386000 Open source
20232023-12-31	Net margin	-14,274.5%	Net Income: -50389000 Open source Revenue: 353000 Open source
20242024-12-31	Net margin	-27,243.8%	Net Income: -64023000 Open source Revenue: 235000 Open source
20252025-12-31	Net margin	-39,009.5%	Net Income: -74118000 Open source Revenue: 190000 Open source
20192019-12-31	Free cash flow margin	-4,761.1%	Revenue: 422000 Open source Operating Cash Flow: -20013000 Open source Capital Expenditure: 79000 Open source
20202020-12-31	Free cash flow margin	-148.3%	Revenue: 10455000 Open source Operating Cash Flow: -15301000 Open source Capital Expenditure: 202000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -33075000 Open source Capital Expenditure: 192000 Open source
20222022-12-31	Free cash flow margin	-419.1%	Revenue: 10386000 Open source Operating Cash Flow: -41886000 Open source Capital Expenditure: 1641000 Open source
20232023-12-31	Free cash flow margin	-10,605.1%	Revenue: 353000 Open source Operating Cash Flow: -33221000 Open source Capital Expenditure: 4215000 Open source
20242024-12-31	Free cash flow margin	-29,440%	Revenue: 235000 Open source Operating Cash Flow: -69119000 Open source Capital Expenditure: 65000 Open source
20252025-12-31	Free cash flow margin	-32,664.7%	Revenue: 190000 Open source Operating Cash Flow: -61986000 Open source Capital Expenditure: 77000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -62M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-20013000	Operating Cash Flow: -20013000 Open source
20202020-12-31	Operating cash flow	-15301000	Operating Cash Flow: -15301000 Open source
20212021-12-31	Operating cash flow	-33075000	Operating Cash Flow: -33075000 Open source
20222022-12-31	Operating cash flow	-41886000	Operating Cash Flow: -41886000 Open source
20232023-12-31	Operating cash flow	-33221000	Operating Cash Flow: -33221000 Open source
20242024-12-31	Operating cash flow	-69119000	Operating Cash Flow: -69119000 Open source
20252025-12-31	Operating cash flow	-61986000	Operating Cash Flow: -61986000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -62.1M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-20092000	Operating Cash Flow: -20013000 Open source Capital Expenditure: 79000 Open source
20202020-12-31	Free cash flow	-15503000	Operating Cash Flow: -15301000 Open source Capital Expenditure: 202000 Open source
20212021-12-31	Free cash flow	-33267000	Operating Cash Flow: -33075000 Open source Capital Expenditure: 192000 Open source
20222022-12-31	Free cash flow	-43527000	Operating Cash Flow: -41886000 Open source Capital Expenditure: 1641000 Open source
20232023-12-31	Free cash flow	-37436000	Operating Cash Flow: -33221000 Open source Capital Expenditure: 4215000 Open source
20242024-12-31	Free cash flow	-69184000	Operating Cash Flow: -69119000 Open source Capital Expenditure: 65000 Open source
20252025-12-31	Free cash flow	-62063000	Operating Cash Flow: -61986000 Open source Capital Expenditure: 77000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2019-12-31	Liabilities / assets	Not reported	Total Assets: 36188000 Open source
2020-12-31	Liabilities / assets	Not reported	Total Assets: 38726000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 115537000 Open source
2022-12-31	Liabilities / assets	Not reported	Total Assets: 95786000 Open source
2023-12-31	Liabilities / assets	Not reported	Total Assets: 120653000 Open source
2024-12-31	Liabilities / assets	Not reported	Total Assets: 96830000 Open source
2025-12-31	Liabilities / assets	Not reported	Total Assets: 93003000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.3× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	2.47×	Current Assets: 31925000 Open source Current Liabilities: 12923000 Open source
20202020-12-31	Current assets / current liabilities	6.06×	Current Assets: 35531000 Open source Current Liabilities: 5864000 Open source
20212021-12-31	Current assets / current liabilities	18.89×	Current Assets: 113569000 Open source Current Liabilities: 6013000 Open source
20222022-12-31	Current assets / current liabilities	5.83×	Current Assets: 80871000 Open source Current Liabilities: 13862000 Open source
20232023-12-31	Current assets / current liabilities	6.27×	Current Assets: 102992000 Open source Current Liabilities: 16416000 Open source
20242024-12-31	Current assets / current liabilities	5.48×	Current Assets: 81954000 Open source Current Liabilities: 14967000 Open source
20252025-12-31	Current assets / current liabilities	5.3×	Current Assets: 80237000 Open source Current Liabilities: 15148000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 57.86 million Exact value Exact value: -57855000 USD 2016-01-01 – 2016-12-31: -57855000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ATYR PHARMA, INC. · 2016-12-31 ATYR PHARMA, INC. (edgar:1339970) Net Income: -57855000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -57855000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459020001282/life-20200110.xml#318381 Filing: 000156459020001282 The citation records this snapshot. The page link may show a newer release later.	−USD 52.86 million Exact value Exact value: -52861000 USD 2016-01-01 – 2016-12-31: -52861000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ATYR PHARMA, INC. · 2016-12-31 ATYR PHARMA, INC. (edgar:1339970) Operating Cash Flow: -52861000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -52861000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459020001282/life-20200110.xml#346733 Filing: 000156459020001282 The citation records this snapshot. The page link may show a newer release later.	USD 600,000 Exact value Exact value: 600000 USD 2016-01-01 – 2016-12-31: 600000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ATYR PHARMA, INC. · 2016-12-31 ATYR PHARMA, INC. (edgar:1339970) Capital Expenditure: 600000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 600000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459020001282/life-20200110.xml#347364 Filing: 000156459020001282 The citation records this snapshot. The page link may show a newer release later.	−USD 53.46 million Calculation and evidence -52861000 − 600000 USD Exact free cash flow: -53461000 USD 2016-01-01 – 2016-12-31: -52861000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 600000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ATYR PHARMA, INC. · 2016-12-31 ATYR PHARMA, INC. (edgar:1339970) Free cash flow: -53461000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -52861000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459020001282/life-20200110.xml#346733 Filing: 000156459020001282 Input fundies:CapitalExpenditure: 600000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459020001282/life-20200110.xml#347364 Filing: 000156459020001282 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 48.21 million Exact value Exact value: -48207000 USD 2017-01-01 – 2017-12-31: -48207000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ATYR PHARMA, INC. · 2017-12-31 ATYR PHARMA, INC. (edgar:1339970) Net Income: -48207000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48207000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459020013208/life-20191231.xml#198362 Filing: 000156459020013208 The citation records this snapshot. The page link may show a newer release later.	−USD 42.36 million Exact value Exact value: -42364000 USD 2017-01-01 – 2017-12-31: -42364000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ATYR PHARMA, INC. · 2017-12-31 ATYR PHARMA, INC. (edgar:1339970) Operating Cash Flow: -42364000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -42364000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459020013208/life-20191231.xml#230339 Filing: 000156459020013208 The citation records this snapshot. The page link may show a newer release later.	USD 1.31 million Exact value Exact value: 1312000 USD 2017-01-01 – 2017-12-31: 1312000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ATYR PHARMA, INC. · 2017-12-31 ATYR PHARMA, INC. (edgar:1339970) Capital Expenditure: 1312000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1312000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459020013208/life-20191231.xml#230968 Filing: 000156459020013208 The citation records this snapshot. The page link may show a newer release later.	−USD 43.68 million Calculation and evidence -42364000 − 1312000 USD Exact free cash flow: -43676000 USD 2017-01-01 – 2017-12-31: -42364000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1312000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ATYR PHARMA, INC. · 2017-12-31 ATYR PHARMA, INC. (edgar:1339970) Free cash flow: -43676000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -42364000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459020013208/life-20191231.xml#230339 Filing: 000156459020013208 Input fundies:CapitalExpenditure: 1312000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459020013208/life-20191231.xml#230968 Filing: 000156459020013208 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 34.52 million Exact value Exact value: -34515000 USD 2018-01-01 – 2018-12-31: -34515000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ATYR PHARMA, INC. · 2018-12-31 ATYR PHARMA, INC. (edgar:1339970) Net Income: -34515000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -34515000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459021014940/life-20201231.xml#174621 Filing: 000156459021014940 The citation records this snapshot. The page link may show a newer release later.	−USD 31.06 million Exact value Exact value: -31063000 USD 2018-01-01 – 2018-12-31: -31063000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ATYR PHARMA, INC. · 2018-12-31 ATYR PHARMA, INC. (edgar:1339970) Operating Cash Flow: -31063000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31063000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459021014940/life-20201231.xml#209822 Filing: 000156459021014940 The citation records this snapshot. The page link may show a newer release later.	USD 594,000 Exact value Exact value: 594000 USD 2018-01-01 – 2018-12-31: 594000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ATYR PHARMA, INC. · 2018-12-31 ATYR PHARMA, INC. (edgar:1339970) Capital Expenditure: 594000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 594000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459021014940/life-20201231.xml#210451 Filing: 000156459021014940 The citation records this snapshot. The page link may show a newer release later.	−USD 31.66 million Calculation and evidence -31063000 − 594000 USD Exact free cash flow: -31657000 USD 2018-01-01 – 2018-12-31: -31063000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 594000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ATYR PHARMA, INC. · 2018-12-31 ATYR PHARMA, INC. (edgar:1339970) Free cash flow: -31657000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31063000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459021014940/life-20201231.xml#209822 Filing: 000156459021014940 Input fundies:CapitalExpenditure: 594000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459021014940/life-20201231.xml#210451 Filing: 000156459021014940 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 16.22 million Exact value Exact value: -16224000 USD 2019-01-01 – 2019-12-31: -16224000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ATYR PHARMA, INC. · 2019-12-31 ATYR PHARMA, INC. (edgar:1339970) Net Income: -16224000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16224000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007873/life-20221231.htm#1372839 Filing: 000095017023007873 The citation records this snapshot. The page link may show a newer release later.	−USD 20.01 million Exact value Exact value: -20013000 USD 2019-01-01 – 2019-12-31: -20013000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ATYR PHARMA, INC. · 2019-12-31 ATYR PHARMA, INC. (edgar:1339970) Operating Cash Flow: -20013000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20013000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459022010441/life-10k_20211231.htm#1963724 Filing: 000156459022010441 The citation records this snapshot. The page link may show a newer release later.	USD 79,000 Exact value Exact value: 79000 USD 2019-01-01 – 2019-12-31: 79000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ATYR PHARMA, INC. · 2019-12-31 ATYR PHARMA, INC. (edgar:1339970) Capital Expenditure: 79000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 79000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459022010441/life-10k_20211231.htm#1974522 Filing: 000156459022010441 The citation records this snapshot. The page link may show a newer release later.	−USD 20.09 million Calculation and evidence -20013000 − 79000 USD Exact free cash flow: -20092000 USD 2019-01-01 – 2019-12-31: -20013000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 79000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ATYR PHARMA, INC. · 2019-12-31 ATYR PHARMA, INC. (edgar:1339970) Free cash flow: -20092000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20013000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459022010441/life-10k_20211231.htm#1963724 Filing: 000156459022010441 Input fundies:CapitalExpenditure: 79000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459022010441/life-10k_20211231.htm#1974522 Filing: 000156459022010441 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 16.22 million Exact value Exact value: -16224000 USD 2020-01-01 – 2020-12-31: -16224000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ATYR PHARMA, INC. · 2020-12-31 ATYR PHARMA, INC. (edgar:1339970) Net Income: -16224000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16224000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007873/life-20221231.htm#2344200 Filing: 000095017023007873 The citation records this snapshot. The page link may show a newer release later.	−USD 15.3 million Exact value Exact value: -15301000 USD 2020-01-01 – 2020-12-31: -15301000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ATYR PHARMA, INC. · 2020-12-31 ATYR PHARMA, INC. (edgar:1339970) Operating Cash Flow: -15301000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15301000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007873/life-20221231.htm#2057146 Filing: 000095017023007873 The citation records this snapshot. The page link may show a newer release later.	USD 202,000 Exact value Exact value: 202000 USD 2020-01-01 – 2020-12-31: 202000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ATYR PHARMA, INC. · 2020-12-31 ATYR PHARMA, INC. (edgar:1339970) Capital Expenditure: 202000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 202000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007873/life-20221231.htm#2068446 Filing: 000095017023007873 The citation records this snapshot. The page link may show a newer release later.	−USD 15.5 million Calculation and evidence -15301000 − 202000 USD Exact free cash flow: -15503000 USD 2020-01-01 – 2020-12-31: -15301000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 202000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ATYR PHARMA, INC. · 2020-12-31 ATYR PHARMA, INC. (edgar:1339970) Free cash flow: -15503000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15301000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007873/life-20221231.htm#2057146 Filing: 000095017023007873 Input fundies:CapitalExpenditure: 202000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017023007873/life-20221231.htm#2068446 Filing: 000095017023007873 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 33.77 million Exact value Exact value: -33768000 USD 2021-01-01 – 2021-12-31: -33768000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ATYR PHARMA, INC. · 2021-12-31 ATYR PHARMA, INC. (edgar:1339970) Net Income: -33768000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -33768000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017024031584/life-20231231.htm#1583765 Filing: 000095017024031584 The citation records this snapshot. The page link may show a newer release later.	−USD 33.08 million Exact value Exact value: -33075000 USD 2021-01-01 – 2021-12-31: -33075000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ATYR PHARMA, INC. · 2021-12-31 ATYR PHARMA, INC. (edgar:1339970) Operating Cash Flow: -33075000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33075000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017024031584/life-20231231.htm#1387051 Filing: 000095017024031584 The citation records this snapshot. The page link may show a newer release later.	USD 192,000 Exact value Exact value: 192000 USD 2021-01-01 – 2021-12-31: 192000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ATYR PHARMA, INC. · 2021-12-31 ATYR PHARMA, INC. (edgar:1339970) Capital Expenditure: 192000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 192000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017024031584/life-20231231.htm#1393833 Filing: 000095017024031584 The citation records this snapshot. The page link may show a newer release later.	−USD 33.27 million Calculation and evidence -33075000 − 192000 USD Exact free cash flow: -33267000 USD 2021-01-01 – 2021-12-31: -33075000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 192000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ATYR PHARMA, INC. · 2021-12-31 ATYR PHARMA, INC. (edgar:1339970) Free cash flow: -33267000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33075000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017024031584/life-20231231.htm#1387051 Filing: 000095017024031584 Input fundies:CapitalExpenditure: 192000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017024031584/life-20231231.htm#1393833 Filing: 000095017024031584 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 45.34 million Exact value Exact value: -45338000 USD 2022-01-01 – 2022-12-31: -45338000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ATYR PHARMA, INC. · 2022-12-31 ATYR PHARMA, INC. (edgar:1339970) Net Income: -45338000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -45338000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017025038888/atyr-20241231.htm#1887689 Filing: 000095017025038888 The citation records this snapshot. The page link may show a newer release later.	−USD 41.89 million Exact value Exact value: -41886000 USD 2022-01-01 – 2022-12-31: -41886000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ATYR PHARMA, INC. · 2022-12-31 ATYR PHARMA, INC. (edgar:1339970) Operating Cash Flow: -41886000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41886000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017025038888/atyr-20241231.htm#1579200 Filing: 000095017025038888 The citation records this snapshot. The page link may show a newer release later.	USD 1.64 million Exact value Exact value: 1641000 USD 2022-01-01 – 2022-12-31: 1641000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ATYR PHARMA, INC. · 2022-12-31 ATYR PHARMA, INC. (edgar:1339970) Capital Expenditure: 1641000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1641000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017025038888/atyr-20241231.htm#1587775 Filing: 000095017025038888 The citation records this snapshot. The page link may show a newer release later.	−USD 43.53 million Calculation and evidence -41886000 − 1641000 USD Exact free cash flow: -43527000 USD 2022-01-01 – 2022-12-31: -41886000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1641000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ATYR PHARMA, INC. · 2022-12-31 ATYR PHARMA, INC. (edgar:1339970) Free cash flow: -43527000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41886000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017025038888/atyr-20241231.htm#1579200 Filing: 000095017025038888 Input fundies:CapitalExpenditure: 1641000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000095017025038888/atyr-20241231.htm#1587775 Filing: 000095017025038888 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 50.39 million Exact value Exact value: -50389000 USD 2023-01-01 – 2023-12-31: -50389000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ATYR PHARMA, INC. · 2023-12-31 ATYR PHARMA, INC. (edgar:1339970) Net Income: -50389000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50389000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#2000308 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.	−USD 33.22 million Exact value Exact value: -33221000 USD 2023-01-01 – 2023-12-31: -33221000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ATYR PHARMA, INC. · 2023-12-31 ATYR PHARMA, INC. (edgar:1339970) Operating Cash Flow: -33221000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33221000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1664654 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.	USD 4.22 million Exact value Exact value: 4215000 USD 2023-01-01 – 2023-12-31: 4215000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ATYR PHARMA, INC. · 2023-12-31 ATYR PHARMA, INC. (edgar:1339970) Capital Expenditure: 4215000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4215000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1673868 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.	−USD 37.44 million Calculation and evidence -33221000 − 4215000 USD Exact free cash flow: -37436000 USD 2023-01-01 – 2023-12-31: -33221000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 4215000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ATYR PHARMA, INC. · 2023-12-31 ATYR PHARMA, INC. (edgar:1339970) Free cash flow: -37436000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33221000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1664654 Filing: 000133997026000008 Input fundies:CapitalExpenditure: 4215000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1673868 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 64.02 million Exact value Exact value: -64023000 USD 2024-01-01 – 2024-12-31: -64023000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ATYR PHARMA, INC. · 2024-12-31 ATYR PHARMA, INC. (edgar:1339970) Net Income: -64023000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -64023000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1998467 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.	−USD 69.12 million Exact value Exact value: -69119000 USD 2024-01-01 – 2024-12-31: -69119000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ATYR PHARMA, INC. · 2024-12-31 ATYR PHARMA, INC. (edgar:1339970) Operating Cash Flow: -69119000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -69119000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1662903 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.	USD 65,000 Exact value Exact value: 65000 USD 2024-01-01 – 2024-12-31: 65000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ATYR PHARMA, INC. · 2024-12-31 ATYR PHARMA, INC. (edgar:1339970) Capital Expenditure: 65000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 65000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1672159 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.	−USD 69.18 million Calculation and evidence -69119000 − 65000 USD Exact free cash flow: -69184000 USD 2024-01-01 – 2024-12-31: -69119000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 65000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ATYR PHARMA, INC. · 2024-12-31 ATYR PHARMA, INC. (edgar:1339970) Free cash flow: -69184000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -69119000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1662903 Filing: 000133997026000008 Input fundies:CapitalExpenditure: 65000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1672159 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 74.12 million Exact value Exact value: -74118000 USD 2025-01-01 – 2025-12-31: -74118000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ATYR PHARMA, INC. · 2025-12-31 ATYR PHARMA, INC. (edgar:1339970) Net Income: -74118000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -74118000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1996626 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.	−USD 61.99 million Exact value Exact value: -61986000 USD 2025-01-01 – 2025-12-31: -61986000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ATYR PHARMA, INC. · 2025-12-31 ATYR PHARMA, INC. (edgar:1339970) Operating Cash Flow: -61986000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -61986000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1661152 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.	USD 77,000 Exact value Exact value: 77000 USD 2025-01-01 – 2025-12-31: 77000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ATYR PHARMA, INC. · 2025-12-31 ATYR PHARMA, INC. (edgar:1339970) Capital Expenditure: 77000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 77000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1670421 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.	−USD 62.06 million Calculation and evidence -61986000 − 77000 USD Exact free cash flow: -62063000 USD 2025-01-01 – 2025-12-31: -61986000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 77000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ATYR PHARMA, INC. · 2025-12-31 ATYR PHARMA, INC. (edgar:1339970) Free cash flow: -62063000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:40:08Z Snapshot: ea7cd91da4ae701eb46c127a8edf4bfacc2180d98939e42aaba13391246fcf21 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1339970?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -61986000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1661152 Filing: 000133997026000008 Input fundies:CapitalExpenditure: 77000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm#1670421 Filing: 000133997026000008 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

60 filings · 2,463 latest values · 2,463 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001339970, 1339970, ATYR, LIFE, edgar:1339970

Also known as ATYR PHARMA INC, ATYR PHARMA, INC., aTYR PHARMA INC, aTyr Pharma, Inc.

ATYR PHARMA, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation